Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company, announced important data on its share capital as of February 28, 2023. The total number of shares in capital stands at 55,583,768, while the total number of voting rights is 61,651,088. Cellectis focuses on developing cell and gene therapies using its gene-editing platform, TALEN®, and aims to address significant medical needs in oncology and blood disorders. The company's innovative approaches include off-the-shelf CAR-T treatments. Cellectis is traded on both the Nasdaq Global Market under the ticker CLLS and Euronext Growth as ALCLS.

Positive

• Strong share capital with 55,583,768 shares.
• Total voting rights at 61,651,088 enhance shareholder influence.
• Focus on innovative gene-editing therapies addresses unmet medical needs.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
02/28/2023	55,583,768	61,651,088

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contact:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Attachment

• Voting_Rights_PR_February_EN_docx

FAQ

What is the share capital of Cellectis as of February 28, 2023?

As of February 28, 2023, Cellectis has a share capital of 55,583,768 shares.

How many voting rights does Cellectis have?

Cellectis has a total of 61,651,088 voting rights.

What clinical areas does Cellectis focus on?

Cellectis focuses on oncology and blood disorders through its gene-editing therapies.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth as ALCLS.